DE602004027021D1 - Cgrp-rezeptorantagonisten - Google Patents

Cgrp-rezeptorantagonisten

Info

Publication number
DE602004027021D1
DE602004027021D1 DE602004027021T DE602004027021T DE602004027021D1 DE 602004027021 D1 DE602004027021 D1 DE 602004027021D1 DE 602004027021 T DE602004027021 T DE 602004027021T DE 602004027021 T DE602004027021 T DE 602004027021T DE 602004027021 D1 DE602004027021 D1 DE 602004027021D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
compounds
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027021T
Other languages
English (en)
Inventor
Christopher S Burgey
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of DE602004027021D1 publication Critical patent/DE602004027021D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004027021T 2003-04-15 2004-04-09 Cgrp-rezeptorantagonisten Expired - Lifetime DE602004027021D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46410903P 2003-04-15 2003-04-15
PCT/US2004/011254 WO2004091514A2 (en) 2003-04-15 2004-04-09 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
DE602004027021D1 true DE602004027021D1 (de) 2010-06-17

Family

ID=33300105

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027021T Expired - Lifetime DE602004027021D1 (de) 2003-04-15 2004-04-09 Cgrp-rezeptorantagonisten

Country Status (9)

Country Link
US (1) US7205292B2 (de)
EP (1) EP1615914B1 (de)
JP (1) JP4705908B2 (de)
CN (1) CN100572379C (de)
AT (1) ATE466860T1 (de)
AU (1) AU2004229518B2 (de)
CA (1) CA2522024A1 (de)
DE (1) DE602004027021D1 (de)
WO (1) WO2004091514A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1812982B (zh) * 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
AU2004263080B2 (en) * 2003-06-26 2008-12-18 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
US7491713B2 (en) * 2004-01-29 2009-02-17 Merck + Co., Inc. CGRP receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7820647B2 (en) * 2004-05-19 2010-10-26 Basf Aktiengesellschaft 2-substituted pyrimidines and their use as pesticides
CN101072771B (zh) * 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7632832B2 (en) * 2005-01-18 2009-12-15 Merck & Co., Inc. CGRP receptor antagonists
JP2008533147A (ja) * 2005-03-14 2008-08-21 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RS57194B1 (sr) 2005-11-14 2018-07-31 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje
ES2368456T3 (es) 2006-05-02 2011-11-17 Bristol-Myers Squibb Company Compuestos restringidos como antagonistas del receptor de cgrp.
US7470680B2 (en) 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
WO2007133491A1 (en) * 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
WO2008070014A2 (en) * 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
EP3165236B1 (de) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Verfahren zur behandlung von eingeweideschmerz mittels verabreichung von antagonistischen antikörpern gegen calcitoningen-assoziiertes peptid
LT3495392T (lt) 2011-05-20 2021-09-27 H. Lundbeck A/S Anti-cgrp kompozicijos ir jų panaudojimas
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
NZ732875A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
WO2017078123A1 (ja) * 2015-11-06 2017-05-11 第一三共株式会社 ジメトキシベンジル基の脱離方法
BR112019005823A2 (pt) 2016-09-23 2019-06-25 Teva Pharmaceuticals Int Gmbh tratamento para enxaqueca refratária
EP3366286A1 (de) 2017-02-22 2018-08-29 Johannes Keller Verbindungen zur behandlung von sepsis
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA76475B (en) * 1975-03-10 1977-08-31 Ciba Geigy Ag Indolyalkylpiperidines
AU671141B2 (en) * 1992-07-29 1996-08-15 Merck Sharp & Dohme Limited Benzodiazepine derivatives
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
AUPO284396A0 (en) * 1996-10-08 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Benzodiazepine derivatives
JPH11209356A (ja) * 1997-04-21 1999-08-03 Takeda Chem Ind Ltd 縮合環化合物、その製造法及び剤
AU6211499A (en) * 1998-09-30 2000-04-17 Merck & Co., Inc. Benzimidazolinyl piperidines as cgrp ligands
DE19963868A1 (de) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
AU2002346048A1 (en) * 2001-06-07 2002-12-16 Merck And Co., Inc. Benzodiazepine bradykinin antagonists
EP1451173A4 (de) * 2001-11-01 2005-10-26 Icagen Inc Piperidine
SE0104248D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
SE0104250D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Heterocyclic compounds
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1812982B (zh) * 2003-06-26 2010-10-27 默沙东公司 苯并二氮杂*cgrp受体拮抗剂
AU2004263080B2 (en) * 2003-06-26 2008-12-18 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7491713B2 (en) * 2004-01-29 2009-02-17 Merck + Co., Inc. CGRP receptor antagonists

Also Published As

Publication number Publication date
ATE466860T1 (de) 2010-05-15
EP1615914B1 (de) 2010-05-05
JP2007525450A (ja) 2007-09-06
CN100572379C (zh) 2009-12-23
WO2004091514A2 (en) 2004-10-28
AU2004229518A1 (en) 2004-10-28
EP1615914A4 (de) 2008-03-12
US20060194783A1 (en) 2006-08-31
AU2004229518B2 (en) 2010-02-18
WO2004091514A3 (en) 2005-09-15
US7205292B2 (en) 2007-04-17
CA2522024A1 (en) 2004-10-28
CN1802369A (zh) 2006-07-12
EP1615914A2 (de) 2006-01-18
JP4705908B2 (ja) 2011-06-22

Similar Documents

Publication Publication Date Title
ATE466860T1 (de) Cgrp-rezeptorantagonisten
ATE503755T1 (de) Cgrp-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten
TW200505903A (en) CGRP receptor antagonists
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE537170T1 (de) Cgrp-rezeptorantagonisten
DE602004013563D1 (de) Rantagonisten
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2006041830A3 (en) Cgrp receptor antagonists
ATE507880T1 (de) Cgrp-rezeptorantagonisten
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
ATE466853T1 (de) Cgrp-rezeptorantagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R081 Change of applicant/patentee

Ref document number: 1615914

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1615914

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213